AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company based in Latham, New York, that develops devices for vascular disease and cancer treatment. The stock has drawn attention from Wall Street because its published price targets sit far above its recent trading range, raising a straightforward question: can ANGO reach $20 per share?
Four current, credible analyst targets were reviewed, ranging from about $17 to $24. The arithmetic mean is $19.75, which rounds to a central target of $20. Individual views include Canaccord Genuity, which raised its target to $20 from $16 after a strong fiscal 2026 close and reiterated a Buy rating in late October 2026; H.C. Wainwright analyst Yi Chen, who trimmed the target to $18 from $19 in mid-October 2026 while keeping a Buy rating; and Lake Street, which maintains a Buy rating and a $24 target. A fourth firm sits near $17.
The spread between $17 and $24 is unusually wide and reflects a genuine split in opinion. More cautious analysts focus on the company's ongoing losses and the time required for reimbursement to convert into durable procedure growth. More bullish analysts emphasize NanoKnife's expanding prostate-ablation franchise and the potential to broaden into benign prostatic hyperplasia (BPH). The consensus rating is a strong buy, but the target is a calculated average, not a guarantee.
At roughly $12.37, reaching $20 would require an advance of about 62%, a very large move by any standard. The stock's 52-week range runs from about $9.39 to $16.29, so the target would also require a decisive breakout to a new high well beyond anything traded over the past year.
The company's trajectory supports at least the direction of such a move. In fiscal 2027's first quarter, revenue rose 6.9% year over year to $80.9 million, led by 13.2% growth in the Med Tech segment, which now represents roughly 49% of total sales. NanoKnife revenue climbed 29% to $8.3 million on record prostate procedure volumes, and Auryon posted its 21st consecutive quarter of double-digit growth. Management reiterated full-year guidance of $336 million to $341 million in revenue, with Med Tech growth of 12% to 15%.
Still, the company remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis, and the stock trades at roughly 1.6 times trailing sales. Reaching $20 would likely require sustained Med Tech acceleration, meaningful reimbursement expansion, and tangible progress toward profitability.
ANGO currently trades below its 50-day moving average near $14.55, indicating near-term weakness after the stock pulled back from its 52-week high of $16.29. That high now marks the first major resistance level, with psychological resistance near $15 and $16. On the downside, support sits near the $11 area and the 52-week low of approximately $9.39, with $10 as a key psychological level. A move toward $20 would require clearing $16.29 and sustaining a breakout to uncharted territory.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms rarely state a precise window and timelines can differ. Investors should watch quarterly earnings and guidance, NanoKnife procedure volumes and reimbursement milestones, the RELIEF BPH study, the CEO transition, and margin and cash-flow trends. Macroeconomic factors such as interest rates, tariffs, and hospital capital spending also matter for a device maker with lumpy capital-equipment sales.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool helps traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. For those following ANGO or the broader market, these signals can provide an additional, data-oriented layer to a research process.
The $20 central target is the rounded average of four analyst price targets ranging from $17 to $24, and it sits about 62% above the latest price near $12.37. The bull case rests on accelerating Med Tech growth, NanoKnife's expanding reimbursement and clinical pipeline, and improving margins, all backed by a debt-free balance sheet. The bear case centers on ongoing losses, a CEO change, uneven cash conversion, and a wide target range that signals genuine uncertainty about the pace of adoption. Whether ANGO reaches $20 depends on execution and reimbursement momentum that remain unproven; no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ANGO has been loosely correlated with STRRP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ANGO jumps, then STRRP could also see price increases.
| Ticker / NAME | Correlation To ANGO | 1D Price Change % | ||
|---|---|---|---|---|
| ANGO | 100% | -0.41% | ||
| STRRP - ANGO | 48% Loosely correlated | +0.89% | ||
| MXCT - ANGO | 36% Loosely correlated | -13.08% | ||
| ICUI - ANGO | 34% Loosely correlated | +1.82% | ||
| BLCO - ANGO | 33% Poorly correlated | +1.96% | ||
| A - ANGO | 31% Poorly correlated | -1.27% | ||
More | ||||
| Ticker / NAME | Correlation To ANGO | 1D Price Change % |
|---|---|---|
| ANGO | 100% | -0.41% |
| Pharmaceuticals: Other industry (49 stocks) | 36% Loosely correlated | +1.90% |
| Pharmaceuticals industry (151 stocks) | 10% Poorly correlated | +0.95% |